Meeting
2022 ASCO Annual Meeting
Lenvatinib for the treatment of thymic epithelial tumors (TETs): A real-life multicenter experience.
Authors
Jose Carlos Benitez
Gustave Roussy, Villejuif, France
Jose Carlos Benitez , Juan Florez-Arango , Eric Dansin , Giuseppe Giaccone , Clemence Basse , Julien Mazieres , Thomas Pierret , Matteo Giaj Levra , Elvire Pons-Tostivint , Jennifer Arrondeau , Mihaela Aldea , Pascale Missy , Thierry Molina , Nicolas Girard , Benjamin Besse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Thymic Malignancies
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8585)
DOI
10.1200/JCO.2022.40.16_suppl.8585
Abstract #
8585
Poster Bd #
211
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinicogenomic characterization of metastatic thymic epithelial tumors.
First Author: Fatemeh Ardeshir-Larijani
Poster
2020 ASCO Virtual Scientific Program
Low-dose oral etoposide is an active option for patients with heavily pre-treated thymic epithelial tumors.
First Author: Margaret Ottaviano
Poster
2018 ASCO Annual Meeting
A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.
First Author: Matteo Perrino
Poster
2017 ASCO Annual Meeting
A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.
First Author: Jinhyun Cho